Hot Keywords
Tumor Microenvironment Exosomes and Extracellular Vesicles Breast Cancer Metastasis Bone Metastasis Metastatic Renal Cell Carcinoma Lymph node metastasis Mesothelioma Hematological Malignancies Thyroid Cancer Liquid Biopsies Early Diagnosis Lung Cancer Brain Tumors Lymphoma Oncolytic Virus Cervical Cancer Cancer Stem Cells

Top
J Cancer Metastasis Treat 2021;7:62. 10.20517/2394-4722.2021.103 © The Author(s) 2021.
Open Access Review

Regulation and function of angiogenic factors in chronic lymphocytic leukemia

Department of Molecular Biomedicine, Centro de Investigaciones Biológicas Margarita Salas, Consejo Superior de Investigaciones Científicas, Madrid 280140, Spain.

Correspondence to: Dr. Angeles García-Pardo, Centro de Investigaciones Biológicas Margarita Salas, Consejo Superior de Investigaciones Científicas, Ramiro de Maeztu 9, Madrid 28040, Spain. E-mail: gelivejer@gmail.com ; Dr. Javier Redondo-Muñoz, Department of Molecular Biomedicine, Centro de Investigaciones Biológicas Margarita Salas, Ramiro de Maeztu 9, Madrid 28040, Spain. E-mail: javier.redondo@cib.csic.es

    Views:574 | Downloads:203 | Cited:0 | Comments:0 | :1
    Academic Editors: Lucio Miele, Ribatti Domenico, Dominique Bonnet | Copy Editor: Yue-Yue Zhang | Production Editor: Yue-Yue Zhang

    © The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

    Abstract

    Progression of chronic lymphocytic leukemia (CLL) is determined by the localization of malignant cells in lymphoid tissues, where they receive growth and survival signals. CLL cells produce angiogenic factors that are regulated by internal and external stimuli and whose levels vary according to the clinical stage of the disease. Stromal cellular and molecular components in CLL niches disturb the balance of pro- and antiangiogenic molecules in CLL cells and induce an angiogenic switch. Additionally, CLL cells also influence the behavior of microenvironmental cells, inducing endothelial cell proliferation and increasing the angiogenic capacity of macrophages, neutrophils, and other cells present in CLL niches. As a result of these reciprocal functional interactions, bone marrow angiogenesis is frequently increased in CLL and has been proposed as a prognostic marker in early disease. Besides their role in regulating angiogenesis, angiogenic factors are also involved in CLL cell migration and survival, all contributing to disease progression. Angiogenic factors, particularly vascular endothelial growth factor, have therefore been attractive therapeutic targets in CLL and many clinical trials were established in the past years. However, the results of these trials reveal that anti-angiogenic therapies alone are not as efficient as expected and should rather be used in combination with other treatments.

    INTRODUCTION

    Chronic lymphocytic leukemia (CLL), the most common leukemia in Western countries, is characterized by the clonal proliferation and accumulation of CD5+ B lymphocytes in the peripheral blood and lymphoid organs[1-4]. The degree of organ infiltration serves to classify CLL into different clinical stages, following the criteria established by Rai (stages 0-IV)[5] and Binet (stages A-C)[6]. According to these criteria, the CLL stage 0/A represents low-risk, I-II/B is an intermediate-risk, and III-IV/C represents high-risk. CLL staging is also useful to determine the need for treatment. Current therapies for CLL include the combination fludarabine-cyclophosphamide-rituximab, as well as inhibitors of the B-cell receptor (BCR) signaling pathway, such as ibrutinib/acalabrutinib (Bruton’s tyrosine kinase inhibitors) and idelalisib (phosphatidylinositol 3-kinase-δ inhibitor)[7,8]. An increasing number of CLL cases are now been treated with the Bcl-2 antagonist venetoclax, either as monotherapy or combined with other therapeutic agents[7,8]. Although many patients respond to treatment and some achieve remission, CLL remains an incurable disease.

    Clinically, CLL is very heterogenous, with good or poor prognosis mostly determined by the presence of specific markers, particularly mutated (M-CLL) or unmutated (U-CLL) immunoglobulin heavy-chain variable region (IGVH)[1-4]. U-CLL originates from B cells that have not experienced the germinal center and represents an aggressive disease, whereas M-CLL originates from germinal center-differentiated B cells and usually represents a mild form of the malignancy[9]. Other established prognostic markers for CLL are CD38 and CD49d (the α subunit of the α4β1 integrin), whose elevated expression on CLL cells (> 30%) is associated with a poor outcome[10,11]. CLL tumors also accumulate multiple gene mutations and/or deletions, such as those affecting the p53 protein, whose loss of function is related to resistance to chemotherapy[4]. Whole-genome sequencing analyses have identified genes that are recurrently mutated in CLL, including notch1 (NOTCH1) and myeloid differentiation primary response gene 88 (MYD88)[12]. NOTCH1 mutations are mainly detected in U-CLL cases, while MYD88 mutations are predominant in M-CLL[12]. NOTCH1 mutations are also linked to poor CLL prognosis and high CD49d expression[13]. Recurrent mutations have also been found in genes affecting crucial signaling pathways in CLL, such as those induced by the BCR, NF-κB transcription factor, or MAPK-ERK system[4]. Epigenomic changes are also frequent in CLL, with different patterns in U-CLL and M-CLL cases[4].

    CLL progression is determined by the infiltration of bone marrow and secondary lymphoid organs by the malignant cells. This process is mostly mediated by the α4β1 integrin and the chemokine/receptor axes CXCL12/CXCR4 and CCL21/CCR7[14,15]. MMP-9, CD44, particularly the CD44v6 variant, and CD38 have also be shown to play roles in CLL cell migration to tissues[15-17]. Localization in lymphoid niches is beneficial for CLL cells as they receive proliferation and survival signals, which contribute to disease development[18].

    Angiogenesis, the development of new vessels from pre-existing ones, is another feature associated to CLL progression[19-21]. Increased angiogenesis has been observed in the bone marrow and lymph nodes of CLL patients[22-24]. The microvessel density in the bone marrow positively correlates with the clinical stage of CLL[22] and has also been associated with a dysregulation of angiogenic factors[25]. Additionally, increased bone marrow angiogenesis in CLL has been suggested as a possible prognostic marker to determine the risk of progression in early disease[26,27].

    The angiogenic status of CLL tissues is influenced by cells present in the microenvironment, including CLL cells. Indeed, CLL cells are known to establish reciprocal interactions with stromal cellular components[28-30]. These interactions affect cellular functions and modify the CLL cell gene expression pattern, resulting in the so-called “angiogenic switch”[31-33]. This review describes the angiogenic factors produced by CLL cells, their regulation by internal or external factors, and their function in angiogenesis and other cellular processes. We also summarize the anti-angiogenic therapies that have been evaluated in CLL and the results obtained.

    CLL CELLS PRODUCE PRO- AND ANTIANGIOGENIC FACTORS AND THEIR RECEPTORS

    Angiogenic factors produced by CLL cells

    Previous excellent reviews provide a detailed characterization of the angiogenic factors present in CLL and their possible role in the disease[20,21,34,35]. The present review expands and updates the reported studies. CLL cells spontaneously synthesize and secrete pro- and antiangiogenic molecules, including basic fibroblast growth factor (bFGF)[21,34-36], vascular endothelial growth factor (VEGF)[36-38], platelet-derived growth factor (PDGF)[39], thrombospondin-1 (TSP-1)[36], angiopoietin-2 (Ang-2)[36], and matrix metalloproteinase-9 (MMP-9)[40-42] [Figure 1]. The secreted factors are found in the conditioned media of cultured CLL cells as well as in the plasma/serum and urine of CLL patients, and their levels vary during the course of the disease. Several groups have analyzed samples from CLL patients by enzyme-like immunoassays and have demonstrated that elevated levels of bFGF in lymphocytes and plasma correlate with advanced stages of the disease (Rai stage III/IV)[43-45]. In another study, bFGF levels in urine were also higher in CLL patients than in controls, but they did not significantly correlate with the clinical stage[22].

    Figure 1. Angiogenesis mediators in CLL niches. In lymphoid tissues, CLL cells establish bidirectional interactions with immune and resident cells. Crosstalk with stromal cells induces an angiogenic switch in CLL cells. Conversely, CLL cells secrete the indicated angiogenic factors, which influence the behavior of immune and resident cells to favor angiogenesis. CLL cells are also able to recruit and induce a proangiogenic phenotype in immune cells by secreting soluble factors, such as GM/CSF (granulocyte-macrophage colony stimulating factor), CCL3 (C-C Motif Chemokine Ligand 3), CCL4 (C-C Motif Chemokine Ligand 4), and NAMPT (Nicotinamide phosphoribosyltransferase). Both CLL and stromal cells also release exosomes, whose cargo (proteins and miRNAs) allows neovascularization and angiogenesis. CLL: Chronic lymphocytic leukemia; PDGF: platelet-derived growth factor; VEGF: vascular endothelial growth factor; ANG2: angiopoietin-2; TSP-1: thrombospondin-1; MMP-9: matrix metalloproteinase-9; bFGF: basic fibroblast growth factor.

    VEGF is clearly the most studied angiogenic factor in CLL. The human VEGF family comprises five members: VEGF-A, VEGF-B, VEGF-C, VEGF-D, and placental growth factor[46-48]. VEGF-A is the best characterized and comprises five different isoforms (VEGF121, VEGF145, VEGF165, VEGF189, and VEGF206) that arise by alternative splicing of the VEGF gene[46-49]. Using ELISA, Western blot, and RT-PCR analyses of concentrated CLL cell culture media, Chen et al.[38] demonstrated the presence of VEGF121 and VEGF165, with molecular weights of 28 and 42 kDa, respectively. VEGF165 is the predominant form in CLL and the best studied in terms of expression, regulation and signaling; we refer to this isoform as VEGF throughout this review.

    A correlation was found between elevated levels of serum VEGF in early CLL stages (Rai I/II) and the risk of CLL progression/progression-free survival, supporting the role of VEGF as a prognostic marker in this disease[26,50,51]. The amount of plasma PDGF was also higher in CLL patients than in controls and strongly correlated with the levels of VEGF and with advanced stages (Rai II-IV) and poor prognosis markers (ZAP-70 or CD38 positive)[52]. High concentrations of Ang-2 mRNA and plasma protein were also found in several cohorts of CLL patients, with a significant correlation with an aggressive phenotype (unmutated IGHV, CD38 positive), advanced Binet stages (B-C), and shorter survival[53-55]. Similarly, the intracellular and serum concentrations of MMP-9 were higher in CLL than in normal lymphocytes[40-42]. These elevated MMP-9 levels were detectable at early CLL stages[40] and correlated with the risk of disease progression[56,57]. In contrast to the above-mentioned factors, the levels of the antiangiogenic molecule TSP-1[58], both mRNA and protein, were higher in low-risk CLL patients (Rai I/II) than in high-risk patients (Rai stage > II)[36]. The same pattern was observed when TSP-1 was quantitated in the conditioned medium of CLL cells cultured for 24 h[36]. These studies indicate that expression and secretion of pro- and antiangiogenic molecules is an active process in CLL, with a clear proangiogenic switch as disease progresses (see below). Quantitation of these factors, however, is not done routinely in the clinic when diagnosing and staging CLL, and their amounts are usually determined as complementary indicators or for specific studies. Accordingly, the levels of angiogenic factors are not commonly included among the criteria used to decide the initiation of treatment in CLL.

    Expression of angiogenic factor receptors in CLL cells

    bFGF receptors

    Besides producing angiogenic/angiostatic molecules, CLL cells also express some of the receptors for these factors. The family of bFGF receptors comprises four members, FGFR1-4, which are present in nearly all hematopoietic cells and mediate multiple physiological processes. In an initial study, Rosenwald et al.[59] performed gene expression analyses on CLL cells and identified only the FGFR1 transcript, with higher expression in unmutated IgVH cases. However, using Western blotting, immunoprecipitation, and flow cytometry analyses, Sinha et al.[60] demonstrated that CLL cells expressed elevated levels of FGFR3. Low expression of FGFR1, -2, and -4 was also detected but their levels were similar to those observed on normal B-cells. Additional RT-PCR analyses confirmed the predominant expression of FGFR3[60]. Constitutive phosphorylation at Y653/654 tyrosine residues was also observed in this study, suggesting an active signaling role for FGFR3 in CLL.

    VEGF receptors

    Initial analyses on a cohort of 216 CLL patients by Western blot showed the consistent expression of VEGFR2 protein, while VEGFR2 was not detected in control samples[61]. Using ribonuclease protection and RT-PCR analyses on CLL cells from 30 patients, Kay et al.[36] demonstrated the presence of mRNA for VEGF receptor 1 (VEGFR1) and VEGF receptor 2 (VEGFR2). Expression of all three tyrosine kinase VEGF receptors (VEGFR1, VEGFR2, and VEGFR3) at the CLL cell surface was also demonstrated by flow cytometry (13 patient samples) and immunocytochemical (27 patient samples) analyses[62]. The non-enzymatic VEGF receptor neuropilin-1 was also shown to be present in CLL cells, at both mRNA and protein levels, and with a higher expression than in control B-cells[63,64]. VEGF binds to VEGFR1 and VEGFR2 but not to VEGFR3, whose ligands are VEGF-C and -D[46-49]. Although the binding affinity of VEGF to VEGFR1 and VEGFR2 is high, VEGFR2 is the main receptor responsible for delivering intracellular signaling upon interaction with VEGF[20,61]. Therefore, most studies on the CLL system have focused on the functional consequences of the VEGF/VEGFR2 interaction.

    The levels of expression of VEGFR2 in CLL cells are variable. Ferrajoli et al.[61] showed that elevated levels of VEGFR2 protein, measured in cell extracts, correlated with shorter survival. An association between high VEGFR2 expression and advanced Rai stages (III/IV) was also observed in that study, although it was not statistically significant. Conversely, we analyzed the constitutive VEGFR2 expression on 38 CLL samples by flow cytometry and did not find a correlation with Rai/Binet stages[65]. Despite this, high expression of VEGFR2 appears to be a characteristic of CLL cells, suggesting an active role of this receptor in the pathology of the disease.

    Ang-2 and TSP-1 receptors

    The receptor for Ang-2 is Tie-2, one of the two members (Tie-1 and Tie-2) of the Tie receptor tyrosine kinase family[66]. While expression of Tie-1 in CLL cells was early recognized[36,67,68], the expression of Tie-2 on these cells has been controversial. Analyses by PCR and flow cytometry on nine plasma CLL samples failed to show Tie-2 expression, while Tie-2 was present on endothelial cells used as control[69]. Treatment of these CLL cells with various stimuli (CD40L, hypoxia, and stromal/endothelial cells) did not induce Tie-2 expression. In the same study, bone marrow-derived CLL cells expressed Tie-2, detected by PCR and flow cytometry, suggesting a role for the microenvironment in Tie-2 expression on CLL[69].

    Aguirre Palma et al.[68] did not find a constitutive expression of Tie-2 by PCR analyses of peripheral blood CLL cells. However, they observed a transient expression of Tie-2 upon stimulation of these cells with Ang-2. Another study found that a small percentage of peripheral blood CLL cells expressed Tie-2 at the cell surface[70]. Because Tie-2 undergoes rapid internalization upon activation[71] these authors performed intracellular staining and found a moderate positive expression of Tie-2 receptor. CLL cells infiltrating lymph nodes also expressed Tie-2. The presence of Tie-2 was further confirmed by Western blotting and PCR analyses[70]. It therefore appears that expression of the Tie-2 receptor in CLL cells is subjected to modulation by several external factors.

    Two main TSP-1 receptors, CD36 and CD47, are expressed by CLL cells. CD36 expression was initially studied by Rutella et al.[72] on 24 CLL samples. Using flow cytometry and immunofluorescence analyses, they found variable expression of CD36 in most CLL cases. Elevated CD36 expression was associated with advanced disease (Rai stage III/IV, organ infiltration)[72]. CD47 was also shown to be present in CLL cells and to mediate several functions upon binding to TSP-1, including cell death and cytoskeleton reorganization[73,74].

    MMP-9 receptors

    Although MMP-9 is mainly a secreted protease found in soluble form in serum and cell conditioned media, we and others have consistently found MMP-9 at the CLL cell surface[40-42,75]. Using immunoprecipitation with anti-MMP-9 antibodies, function blocking antibodies, siRNA transfection, and immunofluorescence analyses, our group demonstrated that binding of MMP-9 to CLL cells is mediated by a docking complex consisting of α4β1 integrin and a 190 kDa CD44v isoform[75]. Interestingly, silencing either α4β1 integrin or 190 kDa CD44 with specific siRNAs reduced the amount of cell surface-bound MMP-9 and increased the levels of secreted MMP-9, indicating that there is a dynamic traffic between soluble and cell-bound MMP-9 in CLL. Perhaps this could explain why we could not find in our studies a clear association between the expression of membrane-bound MMP-9 and the clinical stage of the disease[76-79]. The ability to bind and retain MMP-9 at their surface appears to be characteristic of CLL cells as it was not observed in normal B-cells[75].

    α4β1 integrin is present in approximately 40% of CLL cases, and there is now extensive evidence showing that the α subunit of this integrin, also known as CD49d, is a strong independent prognostic marker in CLL, associated with an aggressive disease[10,80]. Our studies have shown that, as a receptor for MMP-9, α4β1 integrin contributes to disease progression by regulating CLL cell migration and survival[77-79,81]. This contribution was recently confirmed based on a bimodal pattern of expression of CD49d in CLL cells[82]. CD44 (standard and variant forms) is expressed at high levels in CLL cells and has also been proposed as a prognostic marker, particularly due to its role in CLL cell migration and organ localization[17].

    REGULATION OF ANGIOGENIC FACTORS IN CLL

    Regulation by conditions of the microenvironment - hypoxia

    The constitutive production of angiogenic molecules and their receptors by CLL cells is subjected to regulation by several stimuli. Because progression of CLL is characterized by the migration and localization of malignant cells in lymphoid tissues[18,30], these stimuli are mainly provided by the microenvironment of these tissues. Hypoxia, a common condition in human bone marrow and other tissues, is a key regulator of VEGF in physiological and pathological conditions[20,47,49]. Indeed, hypoxia stabilizes the hypoxia-inducible factor-1α (HIF-1α), a major transcription factor for VEGF, allowing its binding to specific elements in the VEGF promoter and increasing VEGF synthesis and secretion[47,49]. Several authors have shown that, upon a hypoxic stimulus, cultured CLL cells increase their VEGF production, at both mRNA and protein levels[36,38]. Moreover, we and others demonstrated by immunohistochemical analyses that VEGF is present in the bone marrow and lymph nodes of CLL patients, and at higher expression than in normal tissues[38,65]. Kay et al.[36] found that culturing CLL cells under hypoxic conditions also reduced the levels of TSP-1 produced by these cells, thus favoring an angiogenic switch. The levels of PDGF and Ang-2 in CLL cells were also shown to be upregulated by hypoxia[36,52,83].

    Regulation by stromal cells - induction of a proangiogenic phenotype on CLL cells

    Upon migration and localization in lymphoid tissues, CLL cells interact with surrounding stromal cells, establishing an active crosstalk that provides survival and proliferation signals to the malignant cells. The molecular bases of these interactions have been recapitulated in excellent previous reviews[30,84] and involve direct cell-cell contact via adhesion molecules, release of soluble factors such as chemokines, or material exchange via extracellular vesicles [Figure 1]. One important consequence of these cellular interactions is the modification of the gene expression profile of CLL cells, mainly resulting in the upregulation of anti-apoptotic molecules (Bcl-2, Bcl-xL, Mcl-1, and XIAP) and the activation of survival signaling pathways (PI3-K/NF-κB and Notch)[30]. Additionally, the balance of pro- and antiangiogenic factors on CLL cells is also affected by the contact with stromal cells. Kay et al.[31] showed that culturing CLL cells on primary bone marrow-derived stromal cells dramatically increased the secretion of bFGF and reduced the levels of the antiangiogenic molecule TSP-1. In another study, Edelmann et al.[32] performed gene microarray analyses on CLL cells that had been co-cultured with the murine bone marrow fibroblast cell line M2-10B4, either in direct cell-cell contact or separated by Transwell inserts. They found that direct contact with the fibroblastic cells significantly increased VEGF expression at both gene and protein levels and decreased TSP-1 expression. Consistent with this decrease, there was a correlation between advanced CLL (Binet stages B and C) and low TSP-1 plasma levels, in agreement with the studies mentioned above. Additionally, MMP-9 was also dramatically upregulated (25.9-fold change) upon CLL cell contact with the fibroblastic cells, compared with freshly isolated CLL cells[32], a fact also confirmed by Schulz et al.[85]. In line with this upregulation, we showed that culturing CLL cells on primary stromal cells (derived from a CLL patient) for 48 h increases the amount of MMP-9 bound to the CLL cell surface by two-fold[81]. Moreover, CLL cells isolated from the bone marrow or lymph nodes of patients consistently showed higher levels of surface-bound MMP-9 than their peripheral blood counterparts, confirming the increased production of MMP-9 in a pathophysiological context[81]. This MMP-9, which is produced by the CLL cells as well as by stromal cells, likely contributes to the increased angiogenic status observed in CLL tissues (see below).

    Endothelial cells are also an important stromal component of lymphoid tissues [Figure 1]. Maffei et al.[33] showed that physical interaction of CLL cells with human umbilical vein endothelial cells protected CLL cells from spontaneous and drug-induced apoptosis. This interaction was mediated by β1 and β2 integrins, and it also resulted in the modulation of 1944 genes, 1217 upregulated and 727 downregulated, determined by gene microarray analyses[33]. Many of the upregulated genes were related to angiogenesis and included the Ang-2 receptors Tie-1 and Tie-2, VEGFC, TSP-1, MMP-2, and MMP-14, while VEGFR3 was downregulated. The C-C motif chemokine-2 (CCL2), which is known to regulate angiogenesis and recruit monocytes/macrophages to tissues[86], was also significantly upregulated in CLL cells upon coculture with endothelial cells[33]. It can be concluded that, in lymphoid tissues, particularly in the bone marrow, these CLL-produced factors disturb the angiogenic balance and contribute to disease progression.

    Autocrine and inter-regulation among angiogenic factors

    The fact that CLL cells express angiogenic factors and their receptors supports the existence of autocrine and crosstalk regulations of the expression and function of these factors. These regulations may take place on circulating CLL cells as well as in CLL cells located in niches. On isolated CLL cells, Bauvois et al.[40] showed that antibodies to VEGF decreased MMP-9 expression, suggesting a link between both proteins. We showed that binding of VEGF to its VEGFR2 receptor in CLL cells downregulates the expression of MMP-9 as well as the migration of these cells through Matrigel or endothelial cells[87]. Regulation of MMP-9 by the VEGF/VEGFR2 axis was at the transcriptional level and was mediated by the phosphorylation and translocation to the nucleus of the signal transducer and activator of transcription 1 (STAT1)[87], a factor known to suppress MMP-9 gene transcription in response to interferons in several cell systems[88].

    Using immunofluorescence analyses, our group also demonstrated that MMP-9 is present in the bone marrow and lymph nodes of CLL patients, in partial association with the macrophages in these tissues[79]. We studied whether, as a component of the CLL microenvironment, MMP-9 affected the CLL cell angiogenic pattern. Culturing CLL cells on immobilized MMP-9 for 24 h increased the expression of MMP-9 and VEGF and reduced the expression of the angiostatic molecules TSP-1 and Ang-2, all at the gene and protein levels[79], establishing that isolated MMP-9 is able to induce a proangiogenic profile in CLL cells. The fact that MMP-9 interaction with its receptors in CLL cells increases its own production may represent an autocrine positive feedback loop, similar to that described for VEGF in these cells[20].

    Further mechanistic studies demonstrated that downregulation of TSP-1 by MMP-9 involved α4β1 integrin (MMP-9 receptor), Src kinase family activity, and the STAT3 transcription factor[79]. The fact that STAT3 is also a transcription factor for VEGF, regulates the expression and degradation of HIF-1α, and is a key factor in angiogenesis[89-92] strongly suggests that upregulation of VEGF by MMP-9 is also mediated by STAT3 activation.

    Other levels of regulation - epigenetic and gene polymorphism

    Angiogenic molecules in CLL cells can also be regulated through other molecular mechanisms, including gene polymorphisms and epigenetic alterations. The genomic polymorphism in VEGF-A of CLL cells has been extensively studied. According to Lozano-Santos et al.[93], a specific VEGF haplotype correlates with shorter survival in CLL patients. Furthermore, patients who carry this haplotype in combination with other clinical features, such as negative CD38 expression or early age at diagnosis, show a poor survival ratio[93]. Other studies have also indicated that VEGF polymorphism might be relevant as a genetic risk and adverse survival marker in CLL[94,95]. On the other hand, epigenetic profiles might serve to stratify patients and identify different molecular pathways involved in CLL progression. For example, the expression of the Ang-2 gene promoter in CLL cells is highly dependent on the DNA methylation status[96]. This methylation is regulated by VEGF, which promotes Ang-2 expression and neovascularization[96]. In agreement with the notion that DNA methylation regulates critical steps during CLL angiogenesis, it has been reported that Ang-2 expression is also regulated by the tumor suppressor gene microcephalin[97]. Furthermore, other angiogenic molecules such as endothelin-1 are also regulated by DNA methylation in CLL cells[98].

    CONTRIBUTION OF CLL CELLS TO THE ANGIOGENIC STATUS OF LYMPHOID TISSUES

    Functional effects on endothelial cells

    The above-mentioned studies have clearly established that the molecular and cellular components of the microenvironment in CLL tissues modulate the gene expression pattern of CLL cells, inducing a pro-survival and proangiogenic phenotype in the malignant cells. It is also known that modulation of angiogenic molecules in CLL has functional consequences in the CLL niches [Figure 1]. Chen et al.[38] showed that the conditioned medium (CM) of CLL cells cultured for 24 h contained VEGF and induced proliferation of endothelial cells. Moreover, this CM also induced moderate in vitro angiogenesis, and this effect was prevented by a neutralizing anti-VEGF antibody[38]. It was later demonstrated that the CM of cultured CLL cells also contained Ang-2, and the levels of this protein correlated with the degree of bone marrow vascularization of the patients studied[84]. These authors also showed that both Ang-2 and VEGF were responsible for the CM-induced tube formation by endothelial cells on Matrigel matrices, as neutralizing antibodies to either factor diminished the angiogenic effect[83]. In both studies, a hypoxic stimulus further increased the functional effects of the CLL cell CM on endothelial cells. Additionally, we showed that the CM of CLL cells that had been incubated with MMP-9 for 24 h had a significantly higher effect on endothelial cell proliferation compared to the CM of CLL cells incubated on 0.5% BSA[79]. This is likely due to the MMP-9-induced production of proangiogenic factors (MMP-9 and VEGF) by CLL cells mentioned above.

    Functional effects on mesenchymal stromal cells

    Besides affecting endothelial cell behavior, CLL cells also influence the function of other cells present in the microenvironment of CLL niches[29]. An active crosstalk between CLL and mesenchymal stromal cells (MSC), resulting in malignant cell survival and changes in the pattern of cytokine production by MSC, has been reported[99]. Moreover, the CM of CLL cells was shown to drive migration and proliferation of MSC[52]. This effect was mediated by the interaction of the PDGF present in the CM of CLL cells with its PDGFR in mesenchymal cells, which resulted in activation of the receptor and induction of Akt phosphorylation. Binding of the CLL-derived PDGF to PDFGR also induced the production of VEGF (but not bFGF or TSP-1) by mesenchymal cells through a PI3-K-dependent mechanism[52]. This is a clear example of how CLL cells actively modulate their microenvironment, inducing an angiogenic switch that is permissive for CLL progression.

    Functional effects on macrophages

    Macrophages are also important components of tissue microenvironments. In CLL, the specific population of leukemia-associated macrophages, known as nurse-like cells, plays a fundamental role in inducing and maintaining CLL cell proliferation and survival[29,100,101]. The important function of tumor-associated macrophages in angiogenesis is also well documented[102,103]. Macrophages can be activated in vitro by specific stimuli towards two different functional phenotypes: M1 and M2[104]. M1 macrophages are pro-inflammatory and induce strong antitumor immune responses by producing relevant specific molecules and cytotoxic factors. In contrast, M2 macrophages are anti-inflammatory and secrete chemokines/cytokines that suppress immune responses and support tumor expansion[105,106]. In vivo evidence indicates that tumor-associated macrophages are mostly polarized towards the M2-like phenotype and that tumor cells contribute to this polarization[107]. In the case of CLL, Audrito et al.[108] showed that activated CLL cells induced monocyte differentiation to M2 macrophages, and this was mediated by the nicotinamide phosphoribosyltransferase enzyme produced by CLL cells [Figure 1]. These M2 macrophages sustained CLL cell survival and reduced T-cell proliferation, thus favoring disease progression[108]. In another study, the high-mobility group protein B-1 produced by CLL cells was shown to differentiate nurse-like cells to M2-polarized macrophages, concomitant with a STAT3 and NF-κB activation on both cell types[109]. The hypoxic conditions found in CLL niches also indirectly induced M2 macrophage polarization via increase production of adenosine[29].

    Polarization of macrophages towards the M2 subtype also has important consequences for angiogenesis. Zajac et al.[110] showed that M2 macrophages have higher proangiogenic capacity than the M1 subtype, due to the increased production of MMP-9 free of tissue inhibitor of metalloproteinases-1 (TIMP-1), the specific MMP-9 inhibitor. Indeed, these authors showed that M2 macrophages shutdown their TIMP-1 gene expression, a fact that was also demonstrated with murine bone marrow-derived macrophages. The importance of MMP-9 for M2 macrophage angiogenic function was further demonstrated by showing that MMP-9-null M2 macrophages were not angiogenic, despite their downregulation of the TIMP-1 gene[110]. Moreover, the same group showed that neutrophils, which do not produce TIMP-1[111], are the major source of proangiogenic MMP-9 in tumor tissues[112]. MMP-9 is present in CLL tissues, where it is produced by the mentioned stromal cellular components as well as by CLL cells. Our group demonstrated that the CM of 24 h CLL cell cultures induced a proangiogenic profile in both M1 and M2 macrophages after 7 days of culture, as determined by the increased expression of MMP-9 in these cells, at both mRNA and protein levels[79]. Although we did not test whether the MMP-9 produced by M2 macrophages was more angiogenic than that produced by M1 macrophages, this study constitutes another example of how CLL cells modulate the angiogenic profile of microenvironmental cells in CLL tissues.

    Functional effects on neutrophils

    The role of neutrophils in tumor initiation and angiogenesis is well recognized[113]. In solid tumors, such as melanoma, hepatocellular carcinoma, and breast carcinoma, the recruitment of proangiogenic neutrophils triggers STAT3 activation and the production of angiogenic molecules, including VEGF and MMP-9[114]. There is also a proangiogenic subpopulation of neutrophils, which express high levels of α4β1 integrin, CXCR4, and MMP-9 and are recruited to hypoxic tumor sites[115]. Indeed, as mentioned above, inflammatory neutrophils are the major producers of angiogenic MMP-9 in tumor tissues[112]. In the case of CLL, neutrophils were shown to be activated, expressing high levels of CD54 and presenting some functional defects[116]. Podaza et al.[117] showed that CLL cells induced neutrophil survival and their reprogramming to an immunosuppressive phenotype. In turn, neutrophils were shown to affect CLL cell activation and survival through the induction of extracellular traps[117], thus establishing a reciprocal cellular interaction that supports the proangiogenic function of neutrophils in CLL niches.

    Functional effects of CLL cell-derived exosomes

    Exosomes are small extracellular vesicles secreted by normal and malignant cells via exocytosis in response to multiple physiological and pathological conditions[118]. Exosomes contain proteins, DNA, mRNAs and non-coding RNAs (such as miRNAs) that play fundamental roles in cell-cell interactions and tumor-induced microenvironment modifications[119]. Exosomes released by CLL cells were shown to induce the transition of mesenchymal stromal cells to cancer-associated fibroblasts, which support the growth and survival of malignant cells[120]. These exosomes also impacted on endothelial cells increasing angiogenesis in CLL tissues[120] and modulated intracellular signaling pathways on stromal cells, all favoring disease progression[121,122].

    Analysis of the proteomic and miRNA profiles from exosomes produced by CLL cells revealed the presence of several cell surface proteins (CD9, CD37, CD53, CD63, and CD82) and miRNAs, including miR-21, miR-146a, miR-29 family, miR-150, miR-155, and miR-223[120,123] [Table 1]. The expression of some of these miRNAs increases upon BCR activation and has been associated with CLL pathogenesis[123]. Moreover, the expression levels of miR-155 in plasma exosomes were proposed to be a biomarker for the risk of progression from monoclonal B-cell lymphocytosis to CLL, as well as for the identification of CLL patients who may show resistance to therapy[124]. In another study, Farahani et al.[125] showed that exosomes released by CLL cells altered the transcriptome of the stromal cell line HS-5, a fact that may influence the pro-survival signals induced by these cells which favor CLL progression[86].

    Table 1

    Molecular components of stromal and CLL-derived exosomes

    CargoProducer cellCell functionReferences
    Proteins
    S100-A9CLLCLL progression[126]
    CLIC1CLLAngiogenesis[127]
    CD19, CD20 CD37, CD53, and CD82CLLStromal cell activation[120]
    AxlStromal and CLLVEGF production, stromal cell activation[121]
    HLA-DR, ITGA4, Lyn, CD81 and CD37CLLStromal cell proliferation[125]
    CD9, CD63, and CD37CLLCLL activation[123]
    miRNAs
    miR-155CLLCLL progression[124]
    miR-29 family, miR-150, miR-155, and miR-630CLLCLL activation[123]
    miR-21, miR-155, miR-146a, miR-148a, and let-7gCLLStromal cell activation[120]
    miR-202-3p, miR-29a, miR-26, let-7g, and miR-21CLLStromal cell proliferation[125]
    Not identifiedStromalGene expression, CLL migration, CLL survival[128]

    CLL cell-derived exosomes also contain proteins that affect the molecular pathways of recipient cells, including those involved in angiogenesis. For instance, they contain the small calcium-binding protein S100-A9, which regulates the PI3-K/Akt/NF-κB signaling pathway, VEGF production, and inflammatory processes[126]. Another protein present in CLL exosomes is Axl, a receptor tyrosine kinase, which induces stromal cell activation, VEGF production, and CLL progression[121]. Moreover, the chloride intracellular channel 1 protein, also found in CLL exosomes, was recently shown to induce endothelial cell proliferation and angiogenesis through upregulation of β1 integrin and the MAPK/ERK signaling pathway[127]. It has also been reported that extracellular vesicles from bone marrow stromal cells modify the gene expression pattern in CLL cells, affecting BCR activation and other processes[128]. Uptake of these vesicles also rescued CLL cells from apoptosis and enhanced their migratory capacity in response to the CXCL12 chemokine[128]. Altogether, extracellular vesicles produced by CLL or stromal cells constitute another important way of tumor-microenvironment communication in tissues, with consequences on many processes including angiogenesis in CLL niches. These vesicles thus represent potential therapeutic targets, and several clinical trials are currently addressing this possibility[30].

    OTHER FUNCTIONS OF ANGIOGENIC FACTORS IN CLL

    Besides contributing to the observed increased angiogenesis in CLL niches, several angiogenic factors produced by CLL cells are also able to perform other functions that directly affect disease progression. The best studied functions are the role of these factors in CLL cell migration and survival.

    Function of angiogenic factors in CLL cell migration

    VEGF

    A role of VEGF in CLL cell migration was first inferred by the fact that blocking autocrine VEGF or the VEGFR2 kinase activity reduced the chemokine-induced CLL cell migration through endothelium[129]. This study also showed that chemokine activation of αLβ2 integrin and subsequent transendothelial migration was defective in CLL cells and that stimulation with autocrine VEGF and α4β1 integrin overcame this defect and restored cell motility. Regulation of cell motility by these two proteins appears to be particularly relevant in the migration of CLL cells to lymph nodes, as it was preferentially observed in patients with lymphadenopathy[129]. Another example of VEGF involvement in CLL cell migration is the previously mentioned study[88], in which we showed that binding of exogeneous VEGF to VEGFR2 reduces CLL cell migration in a dose-dependent manner. This effect was mediated by the VEGF/VEGFR2-induced downregulation of MMP-9[88].

    MMP-9

    It is well established that MMPs facilitate cell migration by degrading basement membranes and extracellular matrices, as well as by releasing matrix-bound growth factors and chemokines[130]. It is also well established that many MMPs may display non-catalytic activities, mostly by localizing at the cell surface, either via transmembrane domains (MT-MMPs) or by binding to specific cell surface receptors[131]. MMP-9 is the main MMP expressed by CLL cells and localizes at the cell surface by binding to the α4β1 integrin/CD44v complex[75]. Our group showed that CLL migration in vitro as well as in vivo homing to bone marrow and spleen requires optimal MMP-9 expression, and that above these optimal levels migration is inhibited[75,77]. This was demonstrated using the CLL-derived MEC-1 cell line stably transfected with MMP-9 or empty vector as control, as well as primary CLL cells previously incubated with MMP-9[77]. Inhibition of CLL cell migration by elevated concentrations of MMP-9 was partly due to the downregulation of migration regulatory pathways such as those involving the GTPase RhoA and the kinases Akt, ERK, and FAK, together with the concomitant upregulation of p190RhoGAP (RhoA inhibitor) and PTEN (Akt/ERK/FAK inhibitor)[77]. Moreover, a proteolytically inactive MMP-9 mutant had a partial migration inhibitory effect, indicating that both catalytic and non-catalytic MMP-9 functions were involved[132]. Notably, the dual regulatory role of MMP-9 likely operates in vivo since: (1) CLL cell interaction with stroma increases cell-bound MMP-9[32,81,85]; (2) CLL cells from lymphoid tissues express more MMP-9 than their peripheral blood counterparts[81]; and (3) MMP-9 is present in CLL tissues[79]. Upregulation of MMP-9 in CLL cells and tissues is also induced by α4β1 integrin ligation, chemokine (CXCL12 and CCL21)-receptor interactions, or CD38 interactions[15,42,133]. Elevated levels of MMP-9 in lymphoid tissues would therefore favor the retention of CLL cells in these niches and contribute to disease progression.

    Function of angiogenic factors in CLL cell survival/apoptosis

    VEGF

    Binding of many angiogenic factors to their respective receptors in CLL cells are known to induce signaling pathways that lead to apoptosis resistance and cell survival[20,21,34,35]. It was first demonstrated that culturing CLL cells with VEGF for 24 h significantly decreased spontaneous and chrorambucil-induced apoptosis, and this involved upregulation of the anti-apoptotic molecules myeloid cell leukemia-1 (Mcl-1) and X-linked inhibitor of apoptosis protein (XIAP) via activation of the transcription factor STAT3[134,135]. These authors also showed that the VEGFR1 and VEGFR2 receptors are constitutively phosphorylated in CLL cells and that tyrosine kinase inhibitors or anti-VEGF antibodies inhibited this phosphorylation and STAT3 activation, reduced Mcl-1 and XIAP levels, and induced apoptosis[134,135]. These studies substantiate the presence of a VEGF/VEGFR autocrine pathway that supports CLL cell survival and demonstrate that blocking this pathway results in CLL cell apoptosis. Interestingly, it was further demonstrated that this internal autocrine VEGF survival loop particularly operates in CLL cells expressing the prognostic marker CD38, thus introducing a different VEGF behavior in CD38+ and CD38- CLL cells[136].

    Autocrine VEGF was also shown to mediate the survival effect of CD40 ligand (CD154), a molecule expressed on activated T cells, monocytes, macrophages, and other components of the microenvironment[137]. These authors demonstrated that the anti-apoptotic effect of CD154 required the cooperative signaling provided by both CD40 and VEGFR1, 2, resulting in NF-κB activation and upregulation of the protein survivin[137]. Functional cooperation of VEGF receptors and other cell surface molecules, such as integrins, has been clearly established in the context of endothelial cells and tumor angiogenesis[138]. In CLL cells, we demonstrated that the α4β1 integrin is associated with VEGFR2 and modulates VEGF functions on these cells, including the survival effect induced by exogenous VEGF[65].

    bFGF

    In initial studies, it was shown that elevated intracellular levels of bFGF correlated with CLL cell resistance to fludarabine in vitro and that addition of bFGF delayed apoptosis in fludarabine-treated cells[44]. Using CLL-derived cell lines and primary CLL cells, it was also demonstrated that bFGF delayed fludarabine-induced apoptosis by upregulating Bcl-2, at both mRNA and protein levels[139]. Bcl-2 expression was also shown to positively correlate with the levels of bFGF in serum in the 85 patients studied[140]. In another study, Romanov et al.[141] reported that bFGF suppressed p53 activation in cultured CLL cells exposed to ionizing radiation, mainly by upregulating the p53-inhibitory protein MDM2 (mouse double minute 2). bFGF may thus induce CLL cell survival by several mechanisms. Moreover, the survival activity induced by bFGF interaction with its FGFR3 receptor in CLL cells can be potentiated by the tyrosine kinase Axl, which forms a complex with FGFR3 and modulates its signaling pathway[60].

    Ang-2 and TSP-1

    It was initially reported that Ang-2 induces CLL cell survival after 24 h but that, at longer times, Ang-2 has a pro-apoptotic activity[68]. This was attributed to the transient modulation of the Tie-2 receptor, as well as of caspases and ATP content[68]. However, another study has shown that the Ang-2/Tie-2 axis induces CLL cell survival even after 96 h of treatment[70]. These authors also showed that Tie-2 engagement by Ang-2 activated the PI3-K-Akt signaling pathway, and this was abolished by a Tie-2 kinase inhibitor, which, in fact, induced apoptosis[70]. This study therefore supports an autocrine role of Ang-2 which affects CLL cell survival.

    In contrast to the described pro-survival function of some angiogenic factors, binding of TSP-1 to its receptor CD47 was shown to induce apoptosis in CLL cells[73]. The mechanism involved in this action was independent of caspase activation and was not overcome by survival factors such as IL-4 or γ-interferon. It was later demonstrated that induction of apoptosis by TSP-1-CD47 interaction was mediated by cytoskeleton reorganization, mainly involving the small GTP binding protein Cdc42 and the Wiskott-Aldrich Syndrome protein signaling pathway[74]. Another study has shown that peptides derived from the C-terminal domain of TSP-1 targeted CD47 and efficiently induced apoptosis of CLL cells[142]. This apoptotic effect involved activation of phospholipase C γ-1 and was also observed in vivo when injecting these peptides in a CLL xenograft murine model[142].

    MMP-9

    A role for MMP-9 in CLL cell survival was first demonstrated in co-cultures of CLL and bone marrow stromal cells[143]. These authors showed that blocking the constitutive MMP-9 activity with neutralizing antibodies suppressed the anti-apoptotic effect of stromal cells. We reported that culturing CLL cells on immobilized or soluble MMP-9 prevented their spontaneous apoptosis[81]. The MMP-9 effect was dose-dependent and persisted for the seven days of the assay. Importantly, induction of cell survival did not involve the proteolytic activity of MMP-9 but was mediated by MMP-9 binding to α4β1 integrin and CD44v at the CLL cell surface. Indeed, a catalytically inactive MMP-9 mutant or the isolated hemopexin domain of MMP-9 fully reproduced the survival-supporting function of the molecule. This study further showed that MMP-9 (or its hemopexin domain) binding to these receptors induces an intracellular signaling pathway consisting in Lyn activation, STAT3 phosphorylation, and Mcl-1 upregulation. This pathway was observed in all CLL cases studied and was active in CLL lymphoid tissues[81].

    Besides preventing spontaneous apoptosis, MMP-9 also protected CLL cells from the apoptotic effect of cytotoxic drugs, such as fludarabine or arsenic trioxide[76]. This study showed that both of these compounds transcriptionally upregulated MMP-9, which mainly localized at the CLL cell surface. Blocking MMP-9 with antibodies reduced the protective effect of stromal cells to the apoptotic function of arsenic trioxide or fludarabine.

    Additionally, MMP-9 induced CLL cell drug resistance by modulating the balance of anti- and pro-apoptotic proteins of the Bcl-2 family towards an anti-apoptotic pattern[76]. Induction of cell survival therefore represents another contribution of MMP-9 to CLL progression.

    Other possible roles of angiogenic factors in CLL

    During the course of CLL, approximately 2%-10% of patients develop an aggressive lymphoma, known as Richter’s transformation or Richter’s syndrome[144]. In the CLL phase, risk factors for Richter’s transformation include an advanced clinical stage, presence of poor prognostic markers (unmutated IGVH, CD38, and CD49d), and genetic aberrations/mutations of specific genes (TP53, NOTCH1, and MYC)[144]. Other factors, however, may certainly contribute to the CLL-lymphoma transformation. A recent study used patient-derived samples and murine animal models and elegantly demonstrated that activation of Akt triggers Richter transformation via induction of Notch1 signaling[145]. Although the possible involvement of angiogenic factors in Richter’s transformation has not been directly addressed, it is well known that activation of the PI3-K/Akt pathway is a major signaling event upon binding of several angiogenic factors (VEGF, bFGF, PDGF, and Ang-2) to their respective receptors[48,49,52,70]. It is therefore possible that these factors, which, as explained above, are present at elevated levels in advanced CLL, contribute to Richter’s transformation by activating Akt.

    ANTIANGIOGENIC THERAPY IN CLL

    Despite the development of many new therapies in the last decades targeting specific pathways or molecules, CLL remains an incurable disease. Angiogenesis is a common process in cancer, which helps the growth and dissemination of malignant cells. As in other tumors, angiogenesis provides CLL cells with nutrients and survival signals to facilitate disease progression[20-22]. Targeting angiogenesis thus seems a useful therapeutic strategy against CLL [Table 2]. This section summarizes the results obtained with these antiangiogenic treatments in CLL.

    Table 2

    Tested reagents in antiangiogenic therapy for CLL

    Drug/procedureTargetEffectReferences
    Fludarabine and cyclophosphamide, and rituximabPatients with progressive/advanced CLLNo detectable disease on flow cytometry. Increased ratio of CRR[146]
    FludarabinePatients with Binet stage B CLLDiminished microvessel density in BM. Increased ratio of CRR[147]
    Fludarabine-induction and alemtuzumabPatients with progressive/advanced CLLDiminished microvessel area and CLL and mast cells in BM[148]
    Fludarabine and thalidomide Patients with progressive/advanced CLLDiminished number of CLL cells. Increased CRR and nodular partial remission[153]
    Lenalidomide Patients with relapsed/refractory CLLDiminished number of CLL cells. Increased CRR[155]
    Lenalidomide Patients with relapsed/refractory CLLDiminished CLL survival on HUVEC cells. Diminished microvessel density. Downregulation of VEGF and THBS-1[157]
    Lenalidomide and rituximab Patients with CLL (untreated) and patients with relapsed CLLIncreased apoptosis of CLL cells. Increased ORR. Absence of mutations in the Notch pathway. Diminished baseline β2-microglobulin[161]
    Lenalidomide, fludarabine and rituximabPatients with CLL (untreated) and patients with relapsed CLLIncreased ORR and MRD negativity. Direct effects on TP53 mutation and Notch[161]
    Fludarabine, cyclophosphamide, and lenalidomidePatients with relapsed/refractory CLLIncreased CLL cell death. Increased CRR and ORR[159,160]
    Bevacizumab (AVA) AZD2171 and sunitinib malatePatients with untreated CLLNo complete or partial responses. Declined VEGF levels in plasma (AVA)[165]
    Bevacizumab, pentostatin, cyclophosphamide, and rituximab Patients with untreated CLLIncreased CRR. Increased VEGF levels after treatments. Reduction in CCL3 and CCL4 levels[166]
    Vatalanib and pazopanib Primary samples from CLL patients and healthy donorsIncreased CLL cell apoptosis (Caspase dependent). Decreased levels of Mcl-1. Inactivation of VEGFR. Reduction of tumor growth in xenograft models[167]
    Sorafenib Primary samples from CLL patientsIncreased CLL cell death. Downregulation of Mcl-1. Destabilization of the mitochondrial membrane potential. Caspase activation[169]
    Sorafenib Primary samples from CLL patientsIncreased apoptosis in ZAP70+ CLL cells. Inhibition of ERK pathway. Increased CLL apoptosis in cocultures with nurse-like cells[170]
    Sorafenib and rituximab Primary samples from CLL patients and lymphoma/leukemia cell linesIncreased CLL apoptosis. Downregulation of membrane-bound complement regulatory proteins (mCRPs)[171]
    PF-03084014 and FludarabinePrimary samples from CLL patientsDiminished angiogenesis and CXCL12-induced chemotaxis. Inhibition of Notch pathway. Upregulation of HRK gene and downregulation of MMP-9, IL32, Rac2, and actin polymerization[149]
    Epigallocatechin gallate (EGCG)Primary samples from CLL patientsApoptosis of CLL cells on stromal cocultures[168]

    Fludarabine

    Fludarabine is a purine analogue and a frontline treatment in CLL, alone or combined with other compounds such as rituximab and/or cyclophosphamide[1,7,8,146]. The antiangiogenic role of fludarabine was first assessed by Molica et al.[147] who measured the microvessel density in the bone marrow samples of CLL patients and found that this density decreased after fludarabine treatment. The same authors later evaluated the effect of combining fludarabine with alemtuzumab (anti-CD52 antibody) and found an even more significant reduction of angiogenesis in the bone marrow of CLL patients who had received this treatment[148]. In another study, the combination of fludarabine with the γ-secretase inhibitor PF-03084014 resulted in a synergistic induction of apoptosis and the impairment of angiogenesis and cell migration[149]. Importantly, these synergistic effects were specific for Notch1-mutated CLL cells, known to represent a high-risk form of the disease[149].

    Endothelin receptor inhibitor

    CLL cells express high levels of endothelin receptors, which regulate CLL cell-microenvironment interactions and angiogenesis[98]. Maffei et al.[150] reported that inhibiting endothelin receptors with macitentan impaired CLL cell survival, migration, and proliferation. Macitentan also reduced VEGF expression by decreasing HIF-1α accumulation, thus directly affecting angiogenesis[150].

    Lenalidomide

    The use of inhibitors of the transcription factor NF-κB for the treatment of hematological tumors has been proposed for a long time. Thalidomide was a first-generation drug which downmodulated the levels of angiogenic molecules, such as tumor necrosis factor-α and VEGF[151,152]. Indeed, these two angiogenic factors were downregulated in CLL patients treated with thalidomide in combination with fludarabine[153]. Lenalidomide is a thalidomide analog frequently used as a therapeutic agent in hematological malignancies, including multiple myeloma, myelodysplastic syndrome, and CLL[154]. In CLL, lenalidomide was shown to be very efficient in patients with relapsed or refractory disease[155,156]. Lenalidomide has antiangiogenic and antitumor activity as it downregulates cytokines such as VEGF in CLL patients[157]. However, a clinical trial has reported the appearance of venous thrombosis in approximately 18% of the patients receiving lenalidomide, together with the upregulation of soluble vascular endothelial adhesion molecule 1, tumor necrosis factor-α, and C-reactive protein[158]. Other clinical trials have shown that lenalidomide increases the efficiency of fludarabine and rituximab, although this effect appears to be dependent on specific clinical features of the patients[159-161].

    Bevacizumab and VEGF receptor inhibitors

    Bevacizumab (Avastin, AVA) is a monoclonal antibody targeting VEGF with proven antiangiogenic properties in multiple hematologic malignancies, such as acute myeloid leukemia, CLL, and non-Hodgkin’s lymphoma[162-164]. Despite its potential relevance in the clinic, the administration of bevacizumab, as a single agent, to CLL patients has shown no significant improvement in clinical trials[165]. However, when bevacizumab was given to CLL patients in combination with other conventional therapies (pentostatin, cyclophosphamide, and rituximab), clinical trials have shown that it prolongs the progression free and treatment free survival[166]. Vatalanib and pazopanib are potent orally available VEGF receptor tyrosine kinase inhibitors. Both reagents were shown to efficiently induce apoptosis in CLL cells and diminish tumor growth in murine xenograft models[167]. An additional possible avenue to explore VEGF blockage is through epigallocatechin gallate, a green tea extract component that inhibits the VEGFR activation in CLL cells[34,134,168].

    Kinase inhibitors and other therapies

    Sorafenib is a well-known multikinase inhibitor with proven effective roles in tumor cell signaling, proliferation, and angiogenesis. Sorafenib has been shown to a potent inducer of apoptosis in CLL cells, by a mechanism which involves downregulation of the anti-apoptotic protein Mcl-1[169]. This study also showed that sorafenib was able to overcome the drug resistance effect of stromal cells on CLL cells[169]. Another report has shown that sorafenib blocked the survival signals induced by CXCL12 engagement to its receptor CXCR4, particularly the activation of ERK and MEK kinases, and induced apoptosis in a caspase dependent manner[170]. In another study, sorafenib improved the response of CLL cells to the cytotoxic effect of rituximab or ofatumumab, and this effect involved a decrease in the expression of complement regulatory proteins[171]. It was therefore suggested that sorafenib could constitute a potential second line therapy for refractory CLL patients. Altogether these studies indicate that treatments addressing angiogenic factors and their receptors may constitute a useful approach to treat CLL, particularly when used in combination therapies.

    CONCLUSION

    Increased bone marrow angiogenesis is a common feature found in CLL, and it is widely accepted that it contributes to the pathogenesis of the disease. CLL cells are active contributors to this aberrant angiogenesis, as they produce and secrete many angiogenic factors and express angiogenic receptors. CLL cells in niches establish functional bidirectional interactions with microenvironmental cells, which induce a proangiogenic profile in CLL cells and enhanced the angiogenic capacity of stromal cells. Clinical trials addressing angiogenic factors have proven to be insufficient as single treatments and indicate that these therapies should rather be used in combined treatments. Moreover, CLL cells in tissues receive survival and proliferation signals that contribute to disease progression. Consequently, the CLL microenvironment is now considered a crucial target for treatment, and current therapies are aimed at the signaling pathways induced by CLL cell-microenvironment interactions.

    DECLARATIONS

    Authors’ contributions

    Contributed to the preparation of the manuscript: García-Pardo A, Redondo-Muñoz J

    Availability of data and materials

    Not applicable.

    Financial support and sponsorship

    Work for the author’s laboratory was supported by grants SAF2009-07035, SAF2012-31613, SAF2015-69180-R, PI060400, RD06/0020/0011, RD12/0036/0061 (to García-Pardo A) and SAF2017-86327-R (to Redondo-Muñoz J) from the Ministerio de Ciencia e Innovacion- Fondo Europeo de Desarrollo Regional (FEDER), Madrid; P2010/BMD-2314 from the Comunidad de Madrid/European Union (to García-Pardo A); the Fundación de Investigación Mutua Madrileña (to García-Pardo A); the 2020 Leonardo Grant for Researchers and Cultural Creators (BBVA Foundation) (to Redondo-Muñoz J).

    Conflicts of interest

    Both authors declared that there are no conflicts of interest.

    Ethical approval and consent to participate

    Not applicable.

    Consent for publication

    Not applicable.

    Copyright

    © The Author(s) 2021.

    References

    • 1. Zenz T, Mertens D, Küppers R, Döhner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 2010;10:37-50.

      DOIPubMed
    • 2. Gaidano G, Foà R, Dalla-Favera R. Molecular pathogenesis of chronic lymphocytic leukemia. J Clin Invest 2012;122:3432-8.

      DOIPubMed PMC
    • 3. Hallek M, Shanafelt TD, Eichhorst B. Chronic lymphocytic leukaemia. Lancet 2018;391:1524-37.

      DOIPubMed
    • 4. Delgado J, Nadeu F, Colomer D, Campo E. Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies. Haematologica 2020;105:2205-17.

      DOIPubMed PMC
    • 5. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood 1975;46:219-34.

      PubMed
    • 6. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981;48:198-206.

      DOIPubMed
    • 7. Eichhorst B, Robak T, Montserrat E, et al. ESMO Guidelines Committee. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2021;32:23-33.

      DOIPubMed
    • 8. Fürstenau M, Eichhorst B. Novel agents in chronic lymphocytic leukemia: new combination therapies and strategies to overcome resistance. Cancers (Basel) 2021;13:1336.

      DOIPubMed PMC
    • 9. Seifert M, Sellmann L, Bloehdorn J, et al. Cellular origin and pathophysiology of chronic lymphocytic leukemia. J Exp Med 2012;209:2183-98.

      DOIPubMed PMC
    • 10. Bulian P, Shanafelt TD, Fegan C, et al. CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia. J Clin Oncol 2014;32:897-904.

      DOIPubMed PMC
    • 11. Burgler S. Role of CD38 expression in diagnosis and pathogenesis of chronic lymphocytic leukemia and its potential as therapeutic target. Crit Rev Immunol 2015;35:417-32.

      DOIPubMed
    • 12. Puente XS, Pinyol M, Quesada V, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011;475:101-5.

      DOIPubMed PMC
    • 13. Benedetti D, Tissino E, Pozzo F, et al. NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: link between the NOTCH1 and the NF-κB pathways. Leukemia 2018;32:654-62.

      DOIPubMed
    • 14. Davids MS, Burger JA. Cell trafficking in chronic lymphocytic leukemia. Open J Hematol 2012;3:1.

      DOIPubMed PMC
    • 15. Redondo-Muñoz J, García-Pardo A, Teixidó J. Molecular players in hematologic tumor cell trafficking. Front Immunol 2019;10:156.

      DOIPubMed PMC
    • 16. Malavasi F, Deaglio S, Damle R, Cutrona G, Ferrarini M, Chiorazzi N. CD38 and chronic lymphocytic leukemia: a decade later. Blood 2011;118:3470-8.

      DOIPubMed PMC
    • 17. Gutjahr JC, Greil R, Hartmann TN. The role of CD44 in the pathophysiology of chronic lymphocytic leukemia. Front Immunol 2015;6:177.

      DOIPubMed PMC
    • 18. Burger JA, Gribben JG. The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies. Semin Cancer Biol 2014;24:71-81.

      DOIPubMed
    • 19. Aguayo A, Kantarjian H, Manshouri T, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000;96:2240-5.

      PubMed
    • 20. Shanafelt TD, Kay NE. The clinical and biologic importance of neovascularization and angiogenic signaling pathways in chronic lymphocytic leukemia. Semin Oncol 2006;33:174-85.

      DOIPubMed
    • 21. Letilovic T, Vrhovac R, Verstovsek S, Jaksic B, Ferrajoli A. Role of angiogenesis in chronic lymphocytic leukemia. Cancer 2006;107:925-34.

      DOIPubMed
    • 22. Kini AR, Kay NE, Peterson LC. Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia. Leukemia 2000;14:1414-8.

      DOIPubMed
    • 23. Peterson L, Kini AR. Angiogenesis is increased in B-cell chronic lymphocytic leukemia. Blood 2001;97:2529.

      DOIPubMed
    • 24. Frater JL, Kay NE, Goolsby CL, Crawford SE, Dewald GW, Peterson LC. Dysregulated angiogenesis in B-chronic lymphocytic leukemia: morphologic, immunohistochemical, and flow cytometric evidence. Diagn Pathol 2008;3:16.

      DOIPubMed PMC
    • 25. Negaard HF, Iversen N, Bowitz-Lothe IM, et al. Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors. Leukemia 2009;23:162-9.

      DOIPubMed
    • 26. Molica S, Vacca A, Ribatti D, et al. Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia. Blood 2002;100:3344-51.

      DOIPubMed
    • 27. Molica S, Cutrona G, Vitelli G, et al. Markers of increased angiogenesis and their correlation with biological parameters identifying high-risk patients in early B-cell chronic lymphocytic leukemia. Leuk Res 2007;31:1575-8.

      DOIPubMed
    • 28. Ding W, Nowakowski GS, Knox TR, et al. Bi-directional activation between mesenchymal stem cells and CLL B-cells: implication for CLL disease progression. Br J Haematol 2009;147:471-83.

      DOIPubMed PMC
    • 29. Attekum MH, Eldering E, Kater AP. Chronic lymphocytic leukemia cells are active participants in microenvironmental cross-talk. Haematologica 2017;102:1469-76.

      DOIPubMed PMC
    • 30. Dubois N, Crompot E, Meuleman N, Bron D, Lagneaux L, Stamatopoulos B. Importance of crosstalk between chronic lymphocytic leukemia cells and the stromal microenvironment: direct contact, soluble factors, and extracellular vesicles. Front Oncol 2020;10:1422.

      DOIPubMed PMC
    • 31. Kay NE, Shanafelt TD, Strege AK, Lee YK, Bone ND, Raza A. Bone biopsy derived marrow stromal elements rescue chronic lymphocytic leukemia B-cells from spontaneous and drug induced cell death and facilitates an "angiogenic switch". Leuk Res 2007;31:899-906.

      DOIPubMed PMC
    • 32. Edelmann J, Klein-Hitpass L, Carpinteiro A, et al. Bone marrow fibroblasts induce expression of PI3K/NF-kappaB pathway genes and a pro-angiogenic phenotype in CLL cells. Leuk Res 2008;32:1565-72.

      DOIPubMed
    • 33. Maffei R, Fiorcari S, Bulgarelli J, et al. Physical contact with endothelial cells through β1- and β2- integrins rescues chronic lymphocytic leukemia cells from spontaneous and drug-induced apoptosis and induces a peculiar gene expression profile in leukemic cells. Haematologica 2012;97:952-60.

      DOIPubMed PMC
    • 34. Xia Y, Lu RN, Li J. Angiogenic factors in chronic lymphocytic leukemia. Leuk Res 2012;36:1211-7.

      DOIPubMed
    • 35. Aguirre Palma LM, Gehrke I, Kreuzer KA. Angiogenic factors in chronic lymphocytic leukaemia (CLL): where do we stand? Crit Rev Oncol Hematol 2015;93:225-36.

      DOIPubMed
    • 36. Kay NE, Bone ND, Tschumper RC, et al. B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules. Leukemia 2002;16:911-9.

      DOIPubMed
    • 37. Baban D, Murray J, Earl H, Kerr D, Seymour L. Quantitative analysis of vascular endothelial growth factor expression in chronic lymphocytic leukaemia. Int J Oncol ;1996:8:29-34.

      PubMed
    • 38. Chen H, Treweeke AT, West DC, et al. In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells. Blood 2000;96:3181-7.

      PubMed
    • 39. Ho CL, Hsu LF, Phyliky RL, Li CY. Autocrine expression of platelet-derived growth factor B in B cell chronic lymphocytic leukemia. Acta Haematol 2005;114:133-40.

      DOIPubMed
    • 40. Bauvois B, Dumont J, Mathiot C, Kolb JP. Production of matrix metalloproteinase-9 in early stage B-CLL: suppression by interferons. Leukemia 2002;16:791-8.

      DOIPubMed
    • 41. Kamiguti AS, Lee ES, Till KJ, et al. The role of matrix metalloproteinase 9 in the pathogenesis of chronic lymphocytic leukaemia. Br J Haematol 2004;125:128-40.

      DOIPubMed
    • 42. Redondo-Muñoz J, Escobar-Díaz E, Samaniego R, Terol MJ, García-Marco JA, García-Pardo A. MMP-9 in B-cell chronic lymphocytic leukemia is up-regulated by alpha4beta1 integrin or CXCR4 engagement via distinct signaling pathways, localizes to podosomes, and is involved in cell invasion and migration. Blood 2006;108:3143-51.

      DOIPubMed
    • 43. Duensing S, Atzpodien J. Increased intracellular and plasma levels of basic fibroblast growth factor in B-cell chronic lymphocytic leukemia. Blood 1995;85:1978-80.

      PubMed
    • 44. Menzel T, Rahman Z, Calleja E, et al. Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabine. Blood 1996;87:1056-63.

      PubMed
    • 45. Gora-Tybor J, Blonski JZ, Robak T. Circulating proangiogenic cytokines and angiogenesis inhibitor endostatin in untreated patients with chronic lymphocytic leukemia. Mediators Inflamm 2003;12:167-71.

      DOIPubMed PMC
    • 46. Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond) 2005;109:227-41.

      DOIPubMed
    • 47. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 2006;7:359-71.

      DOIPubMed
    • 48. Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies. Genes Cancer 2011;2:1097-105.

      DOIPubMed PMC
    • 49. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76.

      DOIPubMed
    • 50. Molica S, Vitelli G, Levato D, Gandolfo GM, Liso V. Increased serum levels of vascular endothelial growth factor predict risk of progression in early B-cell chronic lymphocytic leukaemia. Br J Haematol 1999;107:605-10.

      DOIPubMed
    • 51. Molica S, Vitelli G, Levato D, Ricciotti A, Digiesi G. Clinicoprognostic implications of increased serum levels of vascular endothelial growth factor and basic fibroblastic growth factor in early B-cell chronic lymphocytic leukaemia. Br J Cancer 2002;86:31-5.

      DOIPubMed PMC
    • 52. Ding W, Knox TR, Tschumper RC, et al. Platelet-derived growth factor (PDGF)-PDGF receptor interaction activates bone marrow-derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switch. Blood 2010;116:2984-93.

      DOIPubMed PMC
    • 53. Maffei R, Marasca R, Martinelli S, et al. Angiopoietin-2 expression in B-cell chronic lymphocytic leukemia: association with clinical outcome and immunoglobulin heavy-chain mutational status. Leukemia 2007;21:1312-5.

      DOIPubMed
    • 54. Maffei R, Martinelli S, Santachiara R, et al. Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia. Blood 2010;116:584-92.

      DOIPubMed
    • 55. Vrbacky F, Smolej L, Vroblova V, et al. Angiopoietin-2 mRNA expression is increased in chronic lymphocytic leukemia patients with poor prognostic features. Hematology 2010;15:210-4.

      DOIPubMed
    • 56. Molica S, Vitelli G, Levato D, et al. Increased serum levels of matrix metalloproteinase-9 predict clinical outcome of patients with early B-cell chronic lymphocytic leukaemia. Eur J Haematol 2003;70:373-8.

      DOIPubMed
    • 57. Gusella M, Bolzonella C, Paolini R, et al. Plasma matrix metalloprotease 9 correlates with blood lymphocytosis, leukemic cell invasiveness, and prognosis in B-cell chronic lymphocytic leukemia. Tumour Biol 2017;39:1010428317694325.

      DOIPubMed
    • 58. Lopez-Dee Z, Pidcock K, Gutierrez LS. Thrombospondin-1: multiple paths to inflammation. Mediators Inflamm 2011;2011:296069.

      DOIPubMed PMC
    • 59. Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001;194:1639-47.

      DOIPubMed PMC
    • 60. Sinha S, Boysen J, Nelson M, et al. Axl activates fibroblast growth factor receptor pathway to potentiate survival signals in B-cell chronic lymphocytic leukemia cells. Leukemia 2016;30:1431-6.

      DOIPubMed PMC
    • 61. Ferrajoli A, Manshouri T, Estrov Z, et al. High levels of vascular endothelial growth factor receptor-2 correlate with shortened survival in chronic lymphocytic leukemia. Clin Cancer Res 2001;7:795-9.

      PubMed
    • 62. Bairey O, Boycov O, Kaganovsky E, Zimra Y, Shaklai M, Rabizadeh E. All three receptors for vascular endothelial growth factor (VEGF) are expressed on B-chronic lymphocytic leukemia (CLL) cells. Leuk Res 2004;28:243-8.

      DOIPubMed
    • 63. Nowakowski GS, Mukhopadhyay D, Wu X, Kay NE. Neuropilin-1 is expressed by chronic lymphocytic leukemia B cells. Leuk Res 2008;32:1634-6.

      DOIPubMed PMC
    • 64. Piechnik A, Dmoszynska A, Omiotek M, et al. The VEGF receptor, neuropilin-1, represents a promising novel target for chronic lymphocytic leukemia patients. Int J Cancer 2013;133:1489-96.

      DOIPubMed
    • 65. Gutiérrez-González A, Aguilera-Montilla N, Ugarte-Berzal E, et al. α4β1 integrin associates with VEGFR2 in CLL cells and contributes to VEGF binding and intracellular signaling. Blood Adv 2019;3:2144-8.

      DOIPubMed PMC
    • 66. Saharinen P, Jeltsch M, Santoyo MM, Leppänen V, Alitalo K. The TIE receptor family. In: Wheeler DL, Yarden Y, editors. Receptor tyrosine kinases: family and subfamilies. Cham: Springer International Publishing; 2015. p. 743-75.

      DOI
    • 67. Aguayo A, Manshouri T, O'brien S, et al. Clinical relevance of Flt1 and Tie1 angiogenesis receptors expression in B-cell chronic lymphocytic leukemia (CLL). Leuk Res 2001;25:279-85.

      DOIPubMed
    • 68. Palma LM, Flamme H, Gerke I, Kreuzer KA. Angiopoietins modulate survival, migration, and the components of the Ang-Tie2 pathway of chronic lymphocytic leukaemia (CLL) cells in vitro. Cancer Microenviron 2016;9:13-26.

      DOIPubMed PMC
    • 69. Pötzsch B, Gehrke I, Poll-Wolbeck S, Flamme H, Kreuzer KA. Angiopoietin-2/Tie2 signaling in the microenvironment of chronic lymphocytic leukemia (CLL). Res Cancer Tumor 2014;3:6-18.

      DOI
    • 70. Maffei R, Fiorcari S, Martinelli S, et al. Angiopoietin-2 acts as a survival factor for chronic lymphocytic leukemia B cells throughout Tie-2 receptor engagement. Hematol Oncol 2018;36:372-5.

      DOIPubMed
    • 71. Bogdanovic E, Nguyen VP, Dumont DJ. Activation of Tie2 by angiopoietin-1 and angiopoietin-2 results in their release and receptor internalization. J Cell Sci 2006;119:3551-60.

      DOIPubMed
    • 72. Rutella S, Rumi C, Puggioni P, Barberi, Di Mario A, et al. Expression of thrombospondin receptor (CD36) in B-cell chronic lymphocytic leukemia as an indicator of tumor cell dissemination. Haematologica 1999;84:419-24.

      PubMed
    • 73. Mateo V, Lagneaux L, Bron D, et al. CD47 ligation induces caspase-independent cell death in chronic lymphocytic leukemia. Nat Med 1999;5:1277-84.

      DOIPubMed
    • 74. Mateo V, Brown EJ, Biron G, et al. Mechanisms of CD47-induced caspase-independent cell death in normal and leukemic cells: link between phosphatidylserine exposure and cytoskeleton organization. Blood 2002;100:2882-90.

      DOIPubMed
    • 75. Redondo-Muñoz J, Ugarte-Berzal E, García-Marco JA, et al. Alpha4beta1 integrin and 190-kDa CD44v constitute a cell surface docking complex for gelatinase B/MMP-9 in chronic leukemic but not in normal B cells. Blood 2008;112:169-78.

      DOI
    • 76. Amigo-Jiménez I, Bailón E, Ugarte-Berzal E, Aguilera-Montilla N, García-Marco JA, García-Pardo A. Matrix metalloproteinase-9 is involved in chronic lymphocytic leukemia cell response to fludarabine and arsenic trioxide. PLoS One 2014;9:e99993.

      DOIPubMed PMC
    • 77. Bailón E, Ugarte-Berzal E, Amigo-Jiménez I, et al. Overexpression of progelatinase B/proMMP-9 affects migration regulatory pathways and impairs chronic lymphocytic leukemia cell homing to bone marrow and spleen. J Leukoc Biol 2014;96:185-99.

      DOIPubMed
    • 78. Aguilera-Montilla N, Bailón E, Uceda-Castro R, et al. MMP-9 affects gene expression in chronic lymphocytic leukemia revealing CD99 as an MMP-9 target and a novel partner in malignant cell migration/arrest. Oncogene 2019;38:4605-19.

      DOIPubMed
    • 79. Aguilera-Montilla N, Bailón E, Ugarte-Berzal E, et al. Matrix metalloproteinase-9 induces a pro-angiogenic profile in chronic lymphocytic leukemia cells. Biochem Biophys Res Commun 2019;520:198-204.

      DOIPubMed
    • 80. Cohen JA, Bomben R, Pozzo F, et al. An updated perspective on current prognostic and predictive biomarkers in chronic lymphocytic leukemia in the context of chemoimmunotherapy and novel targeted therapy. Cancers (Basel) 2020;12:894.

      DOIPubMed PMC
    • 81. Redondo-Muñoz J, Ugarte-Berzal E, Terol MJ, et al. Matrix metalloproteinase-9 promotes chronic lymphocytic leukemia b cell survival through its hemopexin domain. Cancer Cell 2010;17:160-72.

      DOIPubMed
    • 82. Tissino E, Pozzo F, Benedetti D, et al. CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression. Blood 2020;135:1244-54.

      DOIPubMed PMC
    • 83. Maffei R, Martinelli S, Castelli I, et al. Increased angiogenesis induced by chronic lymphocytic leukemia B cells is mediated by leukemia-derived Ang2 and VEGF. Leuk Res 2010;34:312-21.

      DOIPubMed
    • 84. Hacken E, Burger JA. Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment. Biochim Biophys Acta 2016;1863:401-13.

      DOIPubMed PMC
    • 85. Schulz A, Toedt G, Zenz T, Stilgenbauer S, Lichter P, Seiffert M. Inflammatory cytokines and signaling pathways are associated with survival of primary chronic lymphocytic leukemia cells in vitro: a dominant role of CCL2. Haematologica 2011;96:408-16.

      DOIPubMed PMC
    • 86. Do HTT, Lee CH, Cho J. Chemokines and their receptors: multifaceted roles in cancer progression and potential value as cancer prognostic markers. Cancers (Basel) 2020;12:287.

      DOIPubMed PMC
    • 87. Ugarte-Berzal E, Redondo-Muñoz J, Eroles P, et al. VEGF/VEGFR2 interaction down-regulates matrix metalloproteinase-9 via STAT1 activation and inhibits B chronic lymphocytic leukemia cell migration. Blood 2010;115:846-9.

      DOIPubMed
    • 88. Ma Z, Qin H, Benveniste EN. Transcriptional suppression of matrix metalloproteinase-9 gene expression by IFN-gamma and IFN-beta: critical role of STAT-1alpha. J Immunol 2001;167:5150-9.

      DOIPubMed
    • 89. Niu G, Wright KL, Huang M, et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002;21:2000-8.

      DOIPubMed
    • 90. Chen Z, Han ZC. STAT3: a critical transcription activator in angiogenesis. Med Res Rev 2008;28:185-200.

      DOIPubMed
    • 91. Badoux X, Bueso-Ramos C, Harris D, et al. Cross-talk between chronic lymphocytic leukemia cells and bone marrow endothelial cells: role of signal transducer and activator of transcription 3. Hum Pathol 2011;42:1989-2000.

      DOIPubMed PMC
    • 92. Gao P, Niu N, Wei T, et al. The roles of signal transducer and activator of transcription factor 3 in tumor angiogenesis. Oncotarget 2017;8:69139-61.

      DOIPubMed PMC
    • 93. Lozano-Santos C, Martinez-Velasquez J, Fernandez-Cuevas B, et al. Vascular endothelial growth factor A (VEGFA) gene polymorphisms have an impact on survival in a subgroup of indolent patients with chronic lymphocytic leukemia. PLoS One 2014;9:e101063.

      DOIPubMed PMC
    • 94. Góra-Tybor J, Szemraj J, Robak T, Jamroziak K. Clinical relevance of vascular endothelial growth factor type A (VEGFA) and VEGF receptor type 2 (VEGFR2) gene polymorphism in chronic lymphocytic leukemia. Blood Cells Mol Dis 2015;54:139-43.

      DOIPubMed
    • 95. Ballester S, Pineda B, Rodrigues P, Tormo E, Terol MJ, Eroles P. Clinical relevance of +936 C>T VEGFA and c.233C>T bFGF polymorphisms in chronic lymphocytic leukemia. Genes (Basel) 2020;11:686.

      DOIPubMed PMC
    • 96. Martinelli S, Kanduri M, Maffei R, et al. ANGPT2 promoter methylation is strongly associated with gene expression and prognosis in chronic lymphocytic leukemia. Epigenetics 2013;8:720-9.

      DOIPubMed PMC
    • 97. Kopparapu PK, Miranda C, Fogelstrand L, et al. MCPH1 maintains long-term epigenetic silencing of ANGPT2 in chronic lymphocytic leukemia. FEBS J 2015;282:1939-52.

      DOIPubMed
    • 98. Martinelli S, Maffei R, Fiorcari S, et al. The expression of endothelin-1 in chronic lymphocytic leukemia is controlled by epigenetic mechanisms and extracellular stimuli. Leuk Res 2017;54:17-24.

      DOIPubMed
    • 99. Trimarco V, Ave E, Facco M, et al. Cross-talk between chronic lymphocytic leukemia (CLL) tumor B cells and mesenchymal stromal cells (MSCs): implications for neoplastic cell survival. Oncotarget 2015;6:42130-49.

      DOIPubMed PMC
    • 100. Mesaros O, Jimbu L, Neaga A, et al. Macrophage polarization in chronic lymphocytic leukemia: nurse-like cells are the caretakers of leukemic cells. Biomedicines 2020;8:516.

      DOIPubMed PMC
    • 101. Fiorcari S, Maffei R, Atene CG, Potenza L, Luppi M, Marasca R. Nurse-like cells and chronic lymphocytic leukemia B cells: a mutualistic crosstalk inside tissue microenvironments. Cells 2021;10:217.

      DOIPubMed PMC
    • 102. Apte RS. Regulation of angiogenesis by macrophages. Adv Exp Med Biol 2010;664:15-9.

      DOIPubMed
    • 103. Riabov V, Gudima A, Wang N, Mickley A, Orekhov A, Kzhyshkowska J. Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis. Front Physiol 2014;5:75.

      DOIPubMed PMC
    • 104. Murray PJ, Allen JE, Biswas SK, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 2014;41:14-20.

      DOIPubMed PMC
    • 105. Jaiswal S, Chao MP, Majeti R, Weissman IL. Macrophages as mediators of tumor immunosurveillance. Trends Immunol 2010;31:212-9.

      DOIPubMed PMC
    • 106. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 2010;11:889-96.

      DOIPubMed
    • 107. Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity 2014;41:49-61.

      DOIPubMed PMC
    • 108. Audrito V, Serra S, Brusa D, et al. Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia. Blood 2015;125:111-23.

      DOIPubMed
    • 109. Jia L, Clear A, Liu FT, et al. Extracellular HMGB1 promotes differentiation of nurse-like cells in chronic lymphocytic leukemia. Blood 2014;123:1709-19.

      DOIPubMed PMC
    • 110. Zajac E, Schweighofer B, Kupriyanova TA, et al. Angiogenic capacity of M1- and M2-polarized macrophages is determined by the levels of TIMP-1 complexed with their secreted proMMP-9. Blood 2013;122:4054-67.

      DOIPubMed PMC
    • 111. Ardi VC, Kupriyanova TA, Deryugina EI, Quigley JP. Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis. Proc Natl Acad Sci U S A 2007;104:20262-7.

      DOIPubMed PMC
    • 112. Deryugina EI, Zajac E, Juncker-Jensen A, Kupriyanova TA, Welter L, Quigley JP. Tissue-infiltrating neutrophils constitute the major in vivo source of angiogenesis-inducing MMP-9 in the tumor microenvironment. Neoplasia 2014;16:771-88.

      DOIPubMed PMC
    • 113. Seignez C, Phillipson M. The multitasking neutrophils and their involvement in angiogenesis. Curr Opin Hematol 2017;24:3-8.

      DOIPubMed
    • 114. Christoffersson G, Vågesjö E, Vandooren J, et al. VEGF-A recruits a proangiogenic MMP-9-delivering neutrophil subset that induces angiogenesis in transplanted hypoxic tissue. Blood 2012;120:4653-62.

      DOIPubMed PMC
    • 115. Massena S, Christoffersson G, Vågesjö E, et al. Identification and characterization of VEGF-A-responsive neutrophils expressing CD49d, VEGFR1, and CXCR4 in mice and humans. Blood 2015;126:2016-26.

      DOIPubMed PMC
    • 116. Manukyan G, Papajik T, Gajdos P, et al. Neutrophils in chronic lymphocytic leukemia are permanently activated and have functional defects. Oncotarget 2017;8:84889-901.

      DOIPubMed PMC
    • 117. Podaza E, Risnik D, Colado A, et al. Chronic lymphocytic leukemia cells increase neutrophils survival and promote their differentiation into CD16high CD62Ldim immunosuppressive subset. Int J Cancer 2019;144:1128-34.

      DOIPubMed
    • 118. Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol 2013;200:373-83.

      DOIPubMed PMC
    • 119. Liu Y, Shi K, Chen Y, et al. Exosomes and their role in cancer progression. Front Oncol 2021;11:639159.

      DOIPubMed PMC
    • 120. Paggetti J, Haderk F, Seiffert M, et al. Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts. Blood 2015;126:1106-17.

      DOIPubMed PMC
    • 121. Ghosh AK, Secreto CR, Knox TR, Ding W, Mukhopadhyay D, Kay NE. Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression. Blood 2010;115:1755-64.

      DOIPubMed PMC
    • 122. Nisticò N, Maisano D, Iaccino E, et al. Role of chronic lymphocytic leukemia (cll)-derived exosomes in tumor progression and survival. Pharmaceuticals (Basel) 2020;13:244.

      DOIPubMed PMC
    • 123. Yeh YY, Ozer HG, Lehman AM, et al. Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling. Blood 2015;125:3297-305.

      DOIPubMed PMC
    • 124. Ferrajoli A, Shanafelt TD, Ivan C, et al. Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. Blood 2013;122:1891-9.

      DOIPubMed PMC
    • 125. Farahani M, Rubbi C, Liu L, Slupsky JR, Kalakonda N. CLL exosomes modulate the transcriptome and behaviour of recipient stromal cells and are selectively enriched in miR-202-3p. PLoS One 2015;10:e0141429.

      DOIPubMed PMC
    • 126. Prieto D, Sotelo N, Seija N, et al. S100-A9 protein in exosomes from chronic lymphocytic leukemia cells promotes NF-κB activity during disease progression. Blood 2017;130:777-88.

      DOIPubMed
    • 127. Geng HY, Feng ZJ, Zhang JJ, Li GY. Exosomal CLIC1 released by CLL promotes HUVECs angiogenesis by regulating ITGβ1-MAPK/ERK axis. Kaohsiung J Med Sci 2021;37:226-35.

      DOIPubMed
    • 128. Crompot E, Van Damme M, Pieters K, et al. Extracellular vesicles of bone marrow stromal cells rescue chronic lymphocytic leukemia B cells from apoptosis, enhance their migration and induce gene expression modifications. Haematologica 2017;102:1594-604.

      DOIPubMed PMC
    • 129. Till KJ, Spiller DG, Harris RJ, Chen H, Zuzel M, Cawley JC. CLL, but not normal, B cells are dependent on autocrine VEGF and alpha4beta1 integrin for chemokine-induced motility on and through endothelium. Blood 2005;105:4813-9.

      DOIPubMed
    • 130. Bonnans C, Chou J, Werb Z. Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol 2014;15:786-801.

      DOIPubMed PMC
    • 131. García-pardo A, Opdenakker G. Nonproteolytic functions of matrix metalloproteinases in pathology and insights for the development of novel therapeutic inhibitors. Metalloproteinases Med 2015;2:19-28.

      DOI
    • 132. Bailón E, Aguilera-Montilla N, Gutiérrez-González A, et al. A catalytically inactive gelatinase B/MMP-9 mutant impairs homing of chronic lymphocytic leukemia cells by altering migration regulatory pathways. Biochem Biophys Res Commun 2018;495:124-30.

      DOIPubMed
    • 133. Vaisitti T, Serra S, Pepper C, et al. CD38 signals upregulate expression and functions of matrix metalloproteinase-9 in chronic lymphocytic leukemia cells. Leukemia 2013;27:1177-81.

      DOIPubMed
    • 134. Lee YK, Bone ND, Strege AK, Shanafelt TD, Jelinek DF, Kay NE. VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia. Blood 2004;104:788-94.

      DOIPubMed
    • 135. Lee YK, Shanafelt TD, Bone ND, Strege AK, Jelinek DF, Kay NE. VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance. Leukemia 2005;19:513-23.

      DOIPubMed
    • 136. Pepper C, Ward R, Lin TT, et al. Highly purified CD38+ and CD38- sub-clones derived from the same chronic lymphocytic leukemia patient have distinct gene expression signatures despite their monoclonal origin. Leukemia 2007;21:687-96.

      DOIPubMed
    • 137. Farahani M, Treweeke AT, Toh CH, et al. Autocrine VEGF mediates the antiapoptotic effect of CD154 on CLL cells. Leukemia 2005;19:524-30.

      DOIPubMed
    • 138. Avraamides CJ, Garmy-Susini B, Varner JA. Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer 2008;8:604-17.

      DOIPubMed PMC
    • 139. König A, Menzel T, Lynen S, et al. Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis. Leukemia 1997;11:258-65.

      DOIPubMed
    • 140. Bairey O, Zimra Y, Shaklai M, Rabizadeh E. Bcl-2 expression correlates positively with serum basic fibroblast growth factor (bFGF) and negatively with cellular vascular endothelial growth factor (VEGF) in patients with chronic lymphocytic leukaemia. Br J Haematol 2001;113:400-6.

      DOIPubMed
    • 141. Romanov VV, James CH, Sherrington PD, Pettitt AR. Basic fibroblast growth factor suppresses p53 activation in the neoplastic cells of a proportion of patients with chronic lymphocytic leukaemia. Oncogene 2005;24:6855-60.

      DOIPubMed
    • 142. Martinez-Torres AC, Quiney C, Attout T, et al. CD47 agonist peptides induce programmed cell death in refractory chronic lymphocytic leukemia B cells via PLCγ1 activation: evidence from mice and humans. PLoS Med 2015;12:e1001796.

      DOIPubMed PMC
    • 143. Ringshausen I, Dechow T, Schneller F, et al. Constitutive activation of the MAPkinase p38 is critical for MMP-9 production and survival of B-CLL cells on bone marrow stromal cells. Leukemia 2004;18:1964-70.

      DOIPubMed
    • 144. Condoluci A, Rossi D. Richter syndrome. Curr Oncol Rep 2021;23:26.

      DOIPubMed PMC
    • 145. Kohlhaas V, Blakemore SJ, Al-Maarri M, et al. Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1. Blood 2021;137:646-60.

      DOIPubMed
    • 146. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23:4079-88.

      DOIPubMed
    • 147. Molica S, Vacca A, Tucc L, Ribatti D. Reversal of bone marrow angiogenesis in chronic lymphocytic leukemia following fludarabine therapy. Haematologica 2005;90:698-700.

      PubMed
    • 148. Molica S, Montillo M, Ribatti D, et al. Intense reversal of bone marrow angiogenesis after sequential fludarabine-induction and alemtuzumab-consolidation therapy in advanced chronic lymphocytic leukemia. Haematologica 2007;92:1367-74.

      PubMed
    • 149. López-Guerra M, Xargay-Torrent S, Rosich L, et al. The γ-secretase inhibitor PF-03084014 combined with fludarabine antagonizes migration, invasion and angiogenesis in NOTCH1-mutated CLL cells. Leukemia 2015;29:96-106.

      DOIPubMed
    • 150. Maffei R, Fiorcari S, Vaisitti T, et al. Macitentan, a double antagonist of endothelin receptors, efficiently impairs migration and microenvironmental survival signals in chronic lymphocytic leukemia. Oncotarget 2017;8:90013-27.

      DOIPubMed PMC
    • 151. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993;177:1675-80.

      DOIPubMed PMC
    • 152. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994;91:4082-5.

      DOIPubMed PMC
    • 153. Chanan-Khan A, Miller KC, Takeshita K, et al. Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL). Blood 2005;106:3348-52.

      DOIPubMed
    • 154. Kotla V, Goel S, Nischal S, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol 2009;2:36.

      DOIPubMed PMC
    • 155. Chanan-Khan A, Miller KC, Musial L, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 2006;24:5343-9.

      DOIPubMed
    • 156. Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008;111:5291-7.

      DOIPubMed PMC
    • 157. Maffei R, Fiorcari S, Bulgarelli J, et al. Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia. Exp Hematol 2014;42:126-36.e1.

      DOIPubMed
    • 158. Aue G, Nelson Lozier J, Tian X, et al. Inflammation, TNFα and endothelial dysfunction link lenalidomide to venous thrombosis in chronic lymphocytic leukemia. Am J Hematol 2011;86:835-40.

      DOIPubMed PMC
    • 159. Egle A, Steurer M, Melchardt T, et al. Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study. Ann Hematol 2018;97:1825-39.

      DOIPubMed PMC
    • 160. Mauro FR, Carella AM, Molica S, et al. Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I-II GIMEMA trial. Leuk Lymphoma 2017;58:1640-7.

      DOIPubMed
    • 161. Strati P, Takahashi K, Peterson CB, et al. Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL. Blood Adv 2019;3:1533-9.

      DOIPubMed PMC
    • 162. Ossenkoppele GJ, Stussi G, Maertens J, et al. Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK). Blood 2012;120:4706-11.

      DOIPubMed
    • 163. Paesler J, Gehrke I, Poll-Wolbeck SJ, Kreuzer KA. Targeting the vascular endothelial growth factor in hematologic malignancies. Eur J Haematol 2012;89:373-84.

      DOIPubMed
    • 164. Bogusz J, Majchrzak A, Mędra A, Cebula-Obrzut B, Robak T, Smolewski P. Mechanisms of action of the anti-VEGF monoclonal antibody bevacizumab on chronic lymphocytic leukemia cells. Postepy Hig Med Dosw (Online) 2013;67:107-18.

      DOIPubMed
    • 165. Shanafelt T, Zent C, Byrd J, et al. Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia. Leuk Lymphoma 2010;51:2222-9.

      DOIPubMed PMC
    • 166. Kay NE, Strati P, LaPlant BR, et al. A randomized phase II trial comparing chemoimmunotherapy with or without bevacizumab in previously untreated patients with chronic lymphocytic leukemia. Oncotarget 2016;7:78269-80.

      DOIPubMed PMC
    • 167. Paesler J, Gehrke I, Gandhirajan RK, et al. The vascular endothelial growth factor receptor tyrosine kinase inhibitors vatalanib and pazopanib potently induce apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo. Clin Cancer Res 2010;16:3390-8.

      DOIPubMed
    • 168. Cornwall S, Cull G, Joske D, Ghassemifar R. Green tea polyphenol "epigallocatechin-3-gallate", differentially induces apoptosis in CLL B-and T-Cells but not in healthy B-and T-Cells in a dose dependant manner. Leuk Res 2016;51:56-61.

      DOIPubMed
    • 169. Huber S, Oelsner M, Decker T, et al. Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1. Leukemia 2011;25:838-47.

      DOIPubMed
    • 170. Messmer D, Fecteau JF, O'Hayre M, Bharati IS, Handel TM, Kipps TJ. Chronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib. Blood 2011;117:882-9.

      DOIPubMed PMC
    • 171. Dwojak M, Bobrowicz M, Bil J, et al. Sorafenib improves rituximab and ofatumumab efficacy by decreasing the expression of complement regulatory proteins. Blood Cancer J 2015;5:e300.

      DOIPubMed PMC

    Cite This Article

    García-Pardo A, Redondo-Muñoz J. Regulation and function of angiogenic factors in chronic lymphocytic leukemia. J Cancer Metastasis Treat 2021;7:62. http://dx.doi.org/10.20517/2394-4722.2021.103

    Views
    574
    Downloads
    203
    Citations
     0
    Comments
    0

    1

    Comments

    Comments must be written in English. Spam, offensive content, impersonation, and private information will not be permitted. If any comment is reported and identified as inappropriate content by OAE staff, the comment will be removed without notice. If you have any queries or need any help, please contact us at support@oaepublish.com.

    © 2016-2022 OAE Publishing Inc., except certain content provided by third parties